In this study, we employed an immunogenic colon cancer model, MC38, which is a hypermutated and immunogenic cancer with mismatch repair deficiency to confirm the efficacy of STING-based immunotherapy 28. This evidence concerns the gene STING1 and colonic neoplasm.